诺迪康品牌怎么样 申请店铺

我要投票 诺迪康在中草药行业中的票数:13 更新时间:2024-11-22
诺迪康是哪个国家的品牌?「诺迪康」是 西藏诺迪康药业股份有限公司 旗下著名品牌。该品牌发源于西藏,由创始人陈达彬在1999-07-14期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
诺迪康怎么样

西藏诺迪康药业股份有限公司是西藏雪域高原上诞生的第一家高新技术制药上市企业,于1999年7月14日创立,1999年7月21日在上海证券交易所上网交易,股票名称:西藏药业,股票代码:600211。

在各级领导的关心和支持下,公司已经发展成为一家拥有员工4000余人,总资产8.2亿元的现代化制药企业。公司累计上缴税金2亿余元,发放员工工资、福利2.2亿余元;公司主要产品诺迪康胶囊年销售额逾亿元,公司生物一类新药重组人脑利钠肽也已经上市销售。

公司拥有西藏诺迪康医药有限公司、成都诺迪康生物制药有限公司、四川诺迪康威光制药有限公司、西藏康达药业有限公司、西藏诺迪康藏药材开发有限公司、四川本草堂药业有限公司等下属子公司。

公司秉承“科学成就健康,健康成就未来”的理念,以科技兴业。在为藏药现代化不遗余力的同时,公司注巨资于生物制品和传统药品的研发,并构建了林芝种植基地和四个生产基地及覆盖全国的营销网络。产品涵盖生物制品、藏药和中药、化学药的产品系列,奠定了西藏药业持续发展的基础,其中具有自主知识产权的生物制品一类新药新活素,代表着目前国际急性心衰急救治疗药物的最高水平,填补了该领域的国内空白。

公司上市以来连续被西藏自治区认定为高新技术企业、西藏自治区农牧业龙头企业,2001年被国家科学技术部认定为国家火炬计划重点高新技术企业。2008年公司被科技部认定为创新型试点企业。公司图形商标(祥云图)经国家工商总局认定为中国驰名商标,公司产品诺迪康胶囊和十味蒂达胶囊被评为国家中药保护品种,同时,还被国家保密局、科学技术部评为秘密级国家秘密技术。

经过多年来的不懈努力,公司已成为拥有一个国家级企业技术中心、四个符合GMP规范的药品生产基地、一个符合GAP藏药材种植基地及覆盖全国的营销网络,集藏药产品、植物药产品、化学药产品、生物制品研发、生产和销售一体的现代化企业。

Tibet nordikang Pharmaceutical Co., Ltd. is the first high-tech pharmaceutical listed enterprise born on the snow capped plateau of Tibet. It was founded on July 14, 1999 and traded on the Internet at Shanghai Stock Exchange on July 21, 1999. Its stock name is Tibet pharmaceutical, and its stock code is 600211. With the concern and support of leaders at all levels, the company has developed into a modern pharmaceutical enterprise with more than 4000 employees and total assets of 820 million yuan. The company has paid taxes of more than 200 million yuan and paid employees salaries and welfare of more than 220 million yuan; the annual sales volume of the company's main product, nordicon capsule, is more than 100 million yuan, and the company's new biological class I recombinant human brain natriuretic peptide has also been listed for sale. The company has subsidiaries including Tibet nordikang Pharmaceutical Co., Ltd., Chengdu nordikang biopharmaceutical Co., Ltd., Sichuan nordikang Weiguang Pharmaceutical Co., Ltd., Tibet Kangda Pharmaceutical Co., Ltd., Tibet nordikang Tibetan Medicine Development Co., Ltd., Sichuan bencaotang Pharmaceutical Co., Ltd. The company adheres to the concept of "science makes health, health makes future", and prospers with science and technology. While sparing no effort for the modernization of Tibetan medicine, the company has invested heavily in the research and development of biological products and traditional drugs, and has built the Linzhi planting base, four production bases and a nationwide marketing network. The products range from biological products, Tibetan medicine, traditional Chinese medicine and chemical medicine, laying the foundation for the sustainable development of Tibetan pharmaceutical industry, among which the biological products with independent intellectual property rights represent the highest level of international emergency treatment drugs for acute heart failure, and fill the domestic gap in this field. Since its listing, the company has been successively recognized as a high-tech enterprise in Tibet Autonomous Region, a leading enterprise in agriculture and animal husbandry in Tibet Autonomous Region, and a key high-tech enterprise in the national torch plan by the Ministry of science and technology of the people's Republic of China in 2001. In 2008, the company was recognized as an innovative pilot enterprise by the Ministry of science and technology. The company's graphic trademark (xiangyuntu) has been recognized as a well-known trademark in China by the State Administration of industry and commerce. The company's products, nordikang capsule and Shiweidida capsule, have been rated as the national traditional Chinese medicine protected varieties. Meanwhile, they have also been rated as the secret level national secret technology by the State Security Bureau and the Ministry of science and technology. After years of unremitting efforts, the company has become a modern enterprise with a national enterprise technology center, four GMP compliant pharmaceutical production bases, a gap compliant Tibetan medicine planting base and a nationwide marketing network, which integrates the research and development, production and sales of Tibetan medicine products, botanical medicine products, chemical medicine products and biological products.

本文链接: https://brand.waitui.com/0b45a7af1.html 联系电话:08916835752

千城特选小程序码

7×24h 快讯

梅花生物:拟105亿日元收购协和发酵旗下的食品氨基酸等业务及资产

36氪获悉,梅花生物发布公告,全资子公司新加坡公司拟以105亿日元(折合人民币约5亿元左右)收购Kirin Holdings Company, Limited(简称“麒麟控股”,东京证券交易所上市公司,股票代码2503.T)的全资子公司Kyowa Hakko Bio Co., Ltd.(协和发酵株式会社,简称“协和发酵”)旗下的食品氨基酸、医药氨基酸、母乳低聚糖业务及资产。

2小时前

三鑫医疗:获得医疗器械注册证

36氪获悉,三鑫医疗发布公告,公司及控股子公司宁波菲拉尔医疗用品有限公司于近日分别获得了国家药监局颁发的血液透析滤过器、一次性使用右心吸引头《医疗器械注册证》。

2小时前

上海电影:拟收购上影元19%股权

36氪获悉,上海电影发布公告,公司拟以现金形式收购控股股东上影集团、上美影分别持有的公司控股子公司上影元(上海)文化科技发展有限公司(简称上影元)14%、5%股权,对应转让价格预计分别为不超过4902.8万元、1751万元。本次交易完成后,上影元股权结构为公司持股70%,上美影持股30%。

2小时前

英国监管机构拟调查苹果与谷歌的移动生态系统活动

英国竞争与市场管理局(CMA)11月22日发布声明称,正考虑根据明年生效的数字市场竞争新规优先调查苹果和谷歌的移动生态系统活动。CMA独立调查小组的研究发现,苹果和谷歌在移动生态系统形成了实际上的“双头垄断”,包括移动设备上的操作系统、应用商店和网络浏览器。该小组认为,苹果的政策阻碍了移动浏览器的创新。CMA表示,将在当地时间12月13日前邀请公众就上述临时调查结果发表评论,预计将在明年3月做出最终决定。(界面)

2小时前

​中晟高科:拟4.57亿元出售中晟新材100%股权

36氪获悉,中晟高科发布公告,公司通过在产权交易中心公开挂牌转让的方式,出售持有的中晟新材100%股权。在首次挂牌信息发布期限内征集到意向受让方泷祥投资,本次标的资产交易对方确定为泷祥投资,交易对价确定为4.57亿元。

2小时前

本页详细列出关于康致寿的品牌信息,含品牌所属公司介绍,康致寿所处行业的品牌地位及优势。
咨询